All manuscripts
Publications CAR T Cells DC Cells NK Cells TIL Cells

Recent Advances in the Development of Bioreactors for Manufacturing of Adoptive Cell Immunotherapies

Published Journal Bioengineering

Share
11 pages Recent Advances in the Development of Bioreactors for Manufacturing of Adoptive Cell Immunotherapies

Overview

This review walks through the equipment available for adoptive cell therapy manufacturing, from culture bags and G-Rex® flasks to rocking-motion, stirred and hollow-fiber bioreactors, and finds no single platform fits every cell type. G-Rex® flasks run on standard laboratory equipment and expand TIL efficiently, though a clinical dose may need up to 30 flasks.

What this paper found

Choosing a bioreactor for adoptive cell therapy manufacturing involves trade-offs between simplicity, scalability and automation, and no single platform suits every cell type. This review compares cell culture bags, G-Rex® flasks, rocking-motion, stirred-flask, stirred-tank and hollow-fiber bioreactors, and semi- or fully automated closed systems such as CliniMACS Prodigy and Cocoon. G-Rex® flasks are affordable, use standard laboratory equipment and expand TILs efficiently, yet producing a clinical TIL dose may require up to 30 flasks, complicating quality control. Rocking-motion bioreactors such as WAVE offer more automation and bag volumes up to 100 L, while automated closed systems cut contamination risk but are costly. One NK cell study found no expansion difference with automation.

Note: This is a narrative review of published systems and does not report new experiments; the authors state that their preference for rocking-motion bioreactors is their own opinion.

Overall, G-Rex flasks have proven to be an affordable and efficient solution for scaling up production without requirements for sophisticated additional equipment. — Irina Ganeeva, Ekaterina Zmievskaya, Aygul Valiullina, Anna Kudriaeva, Regina Miftakhova, Alexey Rybalov, Emil Bulatov, Bioengineering

Study details

Authors
Irina Ganeeva, Ekaterina Zmievskaya, Aygul Valiullina, Anna Kudriaeva, Regina Miftakhova, Alexey Rybalov, Emil Bulatov
Institution
Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan, Russia · Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia · Izvarino Pharma, Moscow, Russia
Journal
Bioengineering
Year
2022
PMID / PMC
PMID: 36551014 · PMC
Cell type(s)
CAR T Cells, DC Cells, NK Cells, TIL Cells

Explore related

Full citation

Ganeeva I, Zmievskaya E, Valiullina A, et al. Recent Advances in the Development of Bioreactors for Manufacturing of Adoptive Cell Immunotherapies. Bioengineering (Basel). 2022;9(12):808.

Building a similar workflow?

Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.

Start a conversation →